Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
13 May 2024
13 May 2024
Historique:
received:
01
03
2024
accepted:
12
04
2024
medline:
14
5
2024
pubmed:
14
5
2024
entrez:
13
5
2024
Statut:
aheadofprint
Résumé
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%), waist circumference (-7.7 cm) and waist-to-height ratio (-6.9%) versus placebo (-1.5%, -1.3 cm and -1.0%, respectively; P < 0.0001 for all comparisons versus placebo). Clinically meaningful weight loss occurred in both sexes and all races, body sizes and regions. Semaglutide was associated with fewer serious adverse events. For each BMI category (<30, 30 to <35, 35 to <40 and ≥40 kg m
Identifiants
pubmed: 38740993
doi: 10.1038/s41591-024-02996-7
pii: 10.1038/s41591-024-02996-7
doi:
Banques de données
ClinicalTrials.gov
['NCT03574597']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Obesity and overweight. World Health Organization https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2021).
Cornier, M. A. et al. Assessing adiposity: a scientific statement from the American Heart Association. Circulation 124, 1996–2019 (2011).
doi: 10.1161/CIR.0b013e318233bc6a
pubmed: 21947291
Afshin, A. et al. Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med. 377, 13–27 (2017).
doi: 10.1056/NEJMoa1614362
pubmed: 28604169
Jensen, M. D. et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J. Am. Coll. Cardiol. 63, 2985–3023 (2014).
doi: 10.1016/j.jacc.2013.11.004
pubmed: 24239920
Poirier, P. et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113, 898–918 (2006).
doi: 10.1161/CIRCULATIONAHA.106.171016
pubmed: 16380542
Dai, H. et al. The global burden of disease attributable to high body mass index in 195 countries and territories, 1990–2017: an analysis of the Global Burden of Disease Study. PLoS Med. 17, e1003198 (2020).
doi: 10.1371/journal.pmed.1003198
pubmed: 32722671
pmcid: 7386577
Ndumele, C. E. et al. Cardiovascular–kidney–metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606–1635 (2023).
doi: 10.1161/CIR.0000000000001184
pubmed: 37807924
Garvey, W. T. et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr. Pr. 22, 1–203 (2016).
doi: 10.4158/EP161365.GL
Ryan, D. H. & Yockey, S. R. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr. Obes. Rep. 6, 187–194 (2017).
doi: 10.1007/s13679-017-0262-y
pubmed: 28455679
pmcid: 5497590
Wing, R. R. et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 34, 1481–1486 (2011).
doi: 10.2337/dc10-2415
pubmed: 21593294
pmcid: 3120182
Wadden, T. A., Tronieri, J. S. & Butryn, M. L. Lifestyle modification approaches for the treatment of obesity in adults. Am. Psychol. 75, 235–251 (2020).
doi: 10.1037/amp0000517
pubmed: 32052997
pmcid: 7027681
Tchang, B. G. et al. Pharmacologic treatment of overweight and obesity in adults. in (eds. Feingold, K. R. et al.) Endotext https://www.ncbi.nlm.nih.gov/books/NBK279038/ (MDText.com, 2000).
Müller, T. D., Blüher, M., Tschöp, M. H. & DiMarchi, R. D. Anti-obesity drug discovery: advances and challenges. Nat. Rev. Drug Discov. 21, 201–223 (2022).
doi: 10.1038/s41573-021-00337-8
pubmed: 34815532
Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021).
doi: 10.1056/NEJMoa2032183
pubmed: 33567185
Wegovy (semaglutide) summary of product characteristics. European Medicines Agency https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf (2023).
WEGOVY (semaglutide) prescribing information. Food and Drug Administration https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf (2023).
Sorli, C. et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 5, 251–260 (2017).
doi: 10.1016/S2213-8587(17)30013-X
pubmed: 28110911
Ozempic (semaglutide) summary of product characteristics. European Medicines Agency https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf (2023).
OZEMPIC (semaglutide) prescribing information. Food and Drug Administration https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf (2017).
Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).
doi: 10.1056/NEJMoa1607141
pubmed: 27633186
Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221–2232 (2023).
doi: 10.1056/NEJMoa2307563
pubmed: 37952131
Ross, R. et al. Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR Working Group on Visceral Obesity. Nat. Rev. Endocrinol. 16, 177–189 (2020).
doi: 10.1038/s41574-019-0310-7
pubmed: 32020062
pmcid: 7027970
Snijder, M. B., van Dam, R. M., Visser, M. & Seidell, J. C. What aspects of body fat are particularly hazardous and how do we measure them? Int. J. Epidemiol. 35, 83–92 (2006).
doi: 10.1093/ije/dyi253
pubmed: 16339600
Lingvay, I. et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity 31, 111–122 (2023).
doi: 10.1002/oby.23621
pubmed: 36502289
Basset, J. The Asia-Pacific perspective: redefining obesity and its treatment. International Diabetes Institute, World Health Organization Regional Office for the Western Pacific, International Association for the Study of Obesity & International Obesity Task Force https://www.vepachedu.org/TSJ/BMI-Guidelines.pdf (2000).
Hu, F. in Obesity Epidemiology (ed. Hu, F.) 53–83 (Oxford University Press, 2008).
Browning, L. M., Hsieh, S. D. & Ashwell, M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0·5 could be a suitable global boundary value. Nutr. Res. Rev. 23, 247–269 (2010).
doi: 10.1017/S0954422410000144
pubmed: 20819243
Sattar, N. et al. Treating chronic diseases without tackling excess adiposity promotes multimorbidity. Lancet Diabetes Endocrinol. 11, 58–62 (2023).
doi: 10.1016/S2213-8587(22)00317-5
pubmed: 36460014
Obesity classification. World Obesity https://www.worldobesity.org/about/about-obesity/obesity-classification (2022).
Unick, J. L. et al. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care 34, 2152–2157 (2011).
doi: 10.2337/dc11-0874
pubmed: 21836103
pmcid: 3177753
Speakman, J. R. et al. Set points, settling points and some alternative models: theoretical options to understand how genes and environments combine to regulate body adiposity. Dis. Model. Mech. 4, 733–745 (2011).
doi: 10.1242/dmm.008698
pubmed: 22065844
pmcid: 3209643
Ryan, D. H. et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am. Heart J. 229, 61–69 (2020).
doi: 10.1016/j.ahj.2020.07.008
pubmed: 32916609